@article{ZahoranovaLuxenhofer2021,
  author    = {Zahoranov{\´a}, Anna and Luxenhofer, Robert},
  title     = {Poly(2-oxazoline)- and Poly(2-oxazine)-Based Self-Assemblies, Polyplexes, and Drug Nanoformulations—An Update},
  series = {Advanced Healthcare Materials},
  volume    = {10},
  journal   = {Advanced Healthcare Materials},
  number    = {6},
  doi       = {10.1002/adhm.202001382},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-225833},
  year      = {2021},
  abstract  = {For many decades, poly(2-oxazoline)s and poly(2-oxazine)s, two closely related families of polymers, have led the life of a rather obscure research topic with only a few research groups world-wide working with them. This has changed in the last five to ten years, presumably triggered significantly by very promising clinical trials of the first poly(2-oxazoline)-based drug conjugate. The huge chemical and structural toolbox poly(2-oxazoline)s and poly(2-oxazine)s has been extended very significantly in the last few years, but their potential still remains largely untapped. Here, specifically, the developments in macromolecular self-assemblies and non-covalent drug delivery systems such as polyplexes and drug nanoformulations based on poly(2-oxazoline)s and poly(2-oxazine)s are reviewed. This highly dynamic field benefits particularly from the extensive synthetic toolbox poly(2-oxazoline)s and poly(2-oxazine)s offer and also may have the largest potential for a further development. It is expected that the research dynamics will remain high in the next few years, particularly as more about the safety and therapeutic potential of poly(2-oxazoline)s and poly(2-oxazine)s is learned.},
  language  = {en}
}